ArticleAnnals of medicine2021
Integrated analysis reveals the participation of IL4I1, ITGB7, and FUT7 in reshaping the TNBC immune microenvironment by targeting glycolysis.
Article in Annals of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Integrated mRNA-miRNA Transcriptome Analysis Reveals the Molecular Mechanism of Tibetan Sheep Rumen Epithelium Adaptation to High Altitude.Animals : an open access journal from MDPI · 2026Article
- Unlocking new therapeutic horizons through integrative bioinformatics and transcriptomics for drug repositioning in breast cancer therapy.Journal of the Egyptian National Cancer Institute · 2026Article
- Epigenetic Regulation of ITGB7 Promotes Coronary Heart Disease via Immune and Metabolic Pathways: A Multimodal Mendelian Randomization Study.Cardiovascular therapeutics · 2026Article
- Structure, function, and implications of fucosyltransferases in health and disease.Nature communications · 2025Review
- Fucosylated N-Glycan Landscape of Triple-Negative Breast Cancer.Molecular cancer research : MCR · 2025Article
- Proteomic Identification of IL4I1 as a Therapeutic Target in P53-Mutant Endometrial Cancer.Cancers · 2025Article
- Glycosylated protein-related microenvironmental features in breast cancer are associated with patient prognosis.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy.International journal of molecular sciences · 2025Review
- ITGB7 Remodels Inflammation and Immune Microenvironment and Enhances Checkpoint Inhibitor-Based Immunotherapy in Pancreatic Cancer.Journal of inflammation research · 2025Article
- IDO1, IL4I1: Novel Immune Checkpoints in Breast Cancer Tumor-Associated Macrophages.Breast cancer (Dove Medical Press) · 2025Article
- Pan-cancer analysis of prognostic and immunological role of IL4I1 in human tumors: a bulk omics research and single cell sequencing validation.Discover oncology · 2024Article
- Article
- Truncated O-glycosylation in metastatic triple-negative breast cancer reveals a gene expression signature associated with extracellular matrix and proteolysis.Scientific reports · 2024Article
- Targeting amino acid-metabolizing enzymes for cancer immunotherapy.Frontiers in immunology · 2024Review
- FUT3 facilitates glucose metabolism of lung adenocarcinoma via activation of NF-κB pathway.BMC pulmonary medicine · 2023Article
- Article
- EccDNA-orientedAnnals of translational medicine · 2022Article
- Integrated multiomic approach for identification of novel immunotherapeutic targets in AML.Biomarker research · 2022Article
- Review
- Analysis of Tumor Glycosylation Characteristics and Implications for Immune Checkpoint Inhibitor's Efficacy for Breast Cancer.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe overall response rate of immunotherapy in triple-negative breast cancer (TNBC) remains unsatisfactory. Accumulating evidence indicated that glucose metabolic reprogramming could modulate immunotherapy efficacy. However, transcriptomic evidence remains insufficient.
methodsGenes' relationship with glucose metabolism and TNBC-specific immune was demonstrated by weighted gene co-expression network analysis (WGCNA). The glucose metabolic capability was estimated by standardised uptake value (SUV), an indicator of glucose uptake in 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET), and a reflection of cancer metabolic behaviour. PD-(L)1 expression was used to reflect the efficacy of immunotherapy. Additionally, immune infiltration, survival, and gene coexpression profiles were provided.
resultsComprehensive analysis revealing that IL4I1, ITGB7, and FUT7 hold the potential to reinforce immunotherapy by reshaping glucose metabolism in TNBC. These results were verified by functional enrichment analysis, which demonstrated their relationships with immune-related signalling pathways and extracellular microenvironment reprogramming. Their expressions have potent positive correlations with Treg and Macrophage cell infiltration and exhausted T cell markers. Meanwhile, their overexpression also lead to poor prognosis.
conclusionIL4I1, ITGB7, and FUT7 may be the hub genes that link glucose metabolism, and cancer-specific immunity. They may be potential targets for enhancing ICB treatment by reprogramming the tumour microenvironment and remodelling tumour metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.